The US Food and Drug Administration is making progress with its implementation of a patient experience data summary section in new drug review documents but there are still inconsistencies, RTI Health Solutions' Ari Gnanasakthy reported at ISPOR's recent annual meeting.
The patient experience data table outlines whether and what patient experience data had been submitted with an application. The FDA began using the table in 2017 to help meet a requirement established by the 21st Century Cures Act that the agency publicly state what patient experience data it reviewed in applications submitted after 12 June 2017
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?